Anaphylaxis events following COVID-19 antiviral and neutralising monoclonal antibody treatment for non-hospitalised patients: data from the OpenSAFELY-TPP platform
Authors:
- Bang ZhengBZBang Zheng
- Amelia Ca GreenAGAmelia Ca Green
- Linda NabLNLinda Nab
- John TazareJTJohn Tazare
- Katie BechmanKBKatie Bechman
- Amir MehrkarAMAmir Mehrkar
- William J HulmeWHWilliam J Hulme
- Brian MacKennaBMBrian MacKenna
- Ben GoldacreBGBen Goldacre
- Ian DouglasIDIan Douglas
- Laurie A TomlinsonLTLaurie A Tomlinson
- The OpenSAFELY CollaborativeTCThe OpenSAFELY Collaborative
Open Access
- 1 September 2023
- journal article
- research article
- Published by F1000 Research Ltd in Wellcome Open Research
- Vol. 8, 387
Abstract
Background: Limited evidence is available regarding the anaphylaxis risk following the administration of COVID-19 therapeutics. Methods: With the approval of NHS England, we conducted a descriptive analysis of anaphylaxis events following COVID-19 treatment for non-hospitalised patients using routine clinical data from 24 million people in England in the OpenSAFELY-TPP database. Results: We found that the risk of anaphylaxis during the 29 days follow-up was 0.04% for sotrovimab users, 0.03% for Paxlovid users, <0.05% for molnupiravir users, and 0.02% for untreated high-risk patients. Conclusions: Our results suggest that anaphylaxis risks were similar between sotrovimab and Paxlovid users, which were not appreciably different from untreated patients.Keywords
Funding Information
- Medical Research Council (MR/V015757/1, MC_PC-20059, MR/W016729/1)
- Health Data Research UK (HDRUK2021.000, 2021.0157)
- UK Research and Innovation (MC_PC_20051, MC_PC_20058)
- Wellcome Trust (222097)
- NIHR (COV-LT-0009, NIHR135559, COV-LT2-0073)
This publication has 1 reference indexed in Scilit: